Cardiff Oncology, Inc.

Welcome to the Cardiff Oncology Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we would ask for a limit of one question and one follow-up question per person. To ask a question at that time, please press star followed by 11 on your touchtone phone. As a reminder, this call is being recorded today, November 2nd, 2023. I would now like to turn the conference call over to Kiki Patel of Gil Martin Group. Please go ahead.

Thank you, Operator. Joining us on the call today from Cardiac Oncology are Chief Executive Officer Mark Erlander and Chief Financial Officer Jamie Levine. During this conference call, management will make forward-looking statements, including, without limitation, statements related to guidance, results, and the timing of data readout for unadvantaged clinical trials. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the company describes in the section titled Risk Factors in our annual report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023. Cardiff Oncology undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. Slides for today's investor call can be found on the homepage and events and presentations tab on the Cardiff Oncology website at www.cardiffoncology.com. With that, I'll turn the call over to Chief Executive Officer Mark Erlander.

Mark. Thank you, Kiki, and good afternoon, everyone, and thank you for joining our third quarter 2023 financial results and the corporate update conference call. As you can see on slide three, this past quarter was transformational. for Cardiff Oncology. In August, we announced strong new data from our lead program in K-RAS mutated metastatic colorectal cancer, the conclusions from a highly supportive meeting with the FDA, and an expansion of our relationship with Pfizer. Then in September, we released data with two earlier stage programs in pancreatic cancer and small cell lung cancer, which included a clear efficacy signal from monvantitive monotherapy in both indications. Today, we would like to put all of this in context and explain our strategy to you all and demonstrate how we can create shareholder value going forward. You know, as we all know, these are challenging times for publicly listed biotech companies. But Cardiff Oncology has a collection of strengths from which to build value. As we list on slide four, These include, first and foremost, our drug, Onvansertib, has shown clear signals of efficacy and tolerability in combination with chemotherapies and as a single agent in our clinical trials across multiple indications. Second, Onvansertib is the only TLK1 specific inhibitor in clinical development, meaning Onvansertib is the first in class molecule for this well-understood target for cancer therapies. Third, Onvansertib can combine synergistically with and is well-tolerated in many first-line and second-line standard of care regimens. This enables us to address some of the most common and deadliest cancer indications in early lines of therapy where there are the large patient populations that could be positively impacted. The fact that we are targeting first-line patients in both metastatic colorectal cancer and pancreatic cancer are good examples of this. Fourth, we have clear third-party support for our plan, and this includes the FDA and Pfizer. And finally, we have the financial resources to pursue our strategy in a thoughtful and methodical manner with the crash runway into 2025. As we go to slide five, we show three objectives for Cardiff Oncology that we believe will create value for all of our stakeholders. And let me be very clear. Our primary focus is our lead program in RAS mutated metastatic colorectal cancer. We are currently working closely with Pfizer Ignite to execute the clinical development plan that the FDA has agreed to. and to generate data from our first-line CARTF004 clinical trial in mid-2024. Our second objective is to continue to generate additional clinical data from our trials in pancreatic cancer, small cell lung cancer, and triple negative breast cancer, which we plan to do in a capital-efficient manner through investigator-initiated trials. Finally, our third objective is rooted in our conviction that PLK1 inhibition has an even larger role to play in cancer therapy. As we have for other clinical programs, we will make data-driven decisions with strong commercial logic to explore new promising combinations and cancer indications. Our current efforts focus on cost-effective preclinical studies. By executing towards these objectives, we can create significant value for all of our stakeholders. And we believe the data and the plans we announced in the third quarter, from a shareholder perspective, reduce the risk of our clinical development plan while increasing the reward potential given the larger commercial opportunity that we are now pursuing. Let's move to slide six. Here, we're summarizing the key accomplishments during the third quarter of our lead program in metastatic colorectal cancer. As you know, in August, we shared a series of findings from our second-line phase 1B2 clinical trial in KRAS-mutated metastatic colorectal cancer. About a quarter of the patients who came into our second-line trial were not treated with bevacupamab or BEV, in their prior first-line treatment. For this Bev-naive patient, we saw strong responses to the combination of our drug on Vansertib with the second-line standard of care, which includes Bev. Specifically, 73% of Bev-naive patients had a confirmed objective response to treatment versus historical controls that had demonstrated a rate around 25%. And these patients also remained on our trial for a median time of 15 months before their disease progressed versus historical controls of seven to eight months. We were highly encouraged by these data, which suggested that there was a new mechanism of action of unvansertive at play that was previously unknown. Observing a threefold increase in response rate, a doubling in the median PFS, in Bev90 patients was a signal too strong for us to ignore. So, as a next step, we investigated the underlying science through a 12-month multi-phase preclinical program. The preclinical work led us to conclude that both on Banserton and Bev have independent mechanisms of action that work together to restrict a tumor's blood supply, thereby significantly decreasing tumor growth. We next asked, why is this clinical finding only observed in BEV-naive patients and not in patients who were treated with BEV in the first-line setting? To answer this question, we engaged an independent research firm called Tempus to conduct a clinical study that analyzed tumor biopsy data from 135 KRAS-mutated metastatic colorectal patients, cancer patients. This analysis showed that once patients were exposed to Bev in the first-line setting, their tumor genomics were changed. And this change is consistent with generating tumor resistance to ambacertib and Bev in the second-line setting. We believe this explains why we observed strong positive clinical results in our Phase 1b2 trial in the BEV-naive, but not the BEV-exposed patient populations. Now, armed out with these findings, we shared our clinical and preclinical data with the FDA in a Type C meeting in June of this year. The FDA suggested we move our clinical development program of OnvancerTIP up to the first line, where all patients are BEV-naive and where we have the opportunity to positively impact the largest patient population of RAS mutated metastatic colorectal cancer. We responded to the FDA's suggestion by proposing a development plan with two clinical trials. The first trial, CARDF004, will provide randomized data for both efficacy and dose confirmation. Then we can conduct a subsequent registrational trial Cardiff 005, where the FDA provided clear guidance for a path to both accelerated approval and full approval from one trial. Finally, we shared the full data package and FDA conclusions with members of our scientific advisory board, which includes a representative from Pfizer. As you know, Pfizer initially invested in Cardiff Oncology two years ago, Having seen full development of the clinical, preclinical, and FDA response I just described, they proposed to us that Pfizer Ignite conduct the CARDF004 first-line clinical trial. Now, every partnership that Pfizer Ignite considers undergoes close internal scrutiny by the chief scientific officer, along with other key scientific team members at Pfizer. They gauge the potential of each project, ensuring collaborations are mutually beneficial and aligned with Pfizer's broader goals. As we announced in August, our new relationship with Pfizer Ignite allows us to leverage their clinical development horsepower to execute our Cardiff 004 clinical trial. While importantly, Cardiff Oncology maintains full economic ownership and control of the answer to. This month, November, the first group of our planned 30 clinical trial sites across the United States for CARTF-004 will be open to enrollment. We anticipate enrolling patients shortly thereafter and plan to report preliminary results in the middle of next year. With this, I'd like to turn now to our earlier stage programs which are highlighted on slide seven. In September, we announced signals of efficacy in metastatic pancreatic cancer from two clinical trials which support our planned path forward in the first-line setting. The first trial, CARTF001, as you know, evaluates on vascular tibs efficacy and tolerability in the second-line setting of pancreatic ductal endocarcinoma or metastatic PDAC. From Cardiff 001, we reported four of our 21 patients, or 19%, achieved an objective partial response, or PR. As of the data cutoff of September 13, 2023, three of the four patients with PRs were still awaiting their confirmatory scans. As of today, November 2, one of these three patients, patient 42, has now shown a further deepening of response at their four-month scan, therefore representing a second confirmed PR on this trial. We are still awaiting confirmatory scans for the remaining two patients with an unconfirmed PR who remain on treatment, one for about eight months and another for over nine months. This is much longer than historical median progression-free survival of 3.1 months for second line. Overall, for all of valuable patients, we reported a median progression-free survival of five months which is encouraging since this approaches the benchmark of the first-line median PFS, which is 5.5 months, indicating yet another strong signal of efficacy in this indication. The second trial in pancreatic cancer is an investigator-initiated biomarker discovery trial in metastatic PDAC, where on VAMSR-TIB's effects on tumors is being evaluated as a single agent. As you recall from our last call, The data we presented in September showed effects on tumor biomarkers with Onvantratib monotherapy after only 10 days of treatment. Because of these encouraging results that we observed today with Onvantratib from both trials, we plan to move to the first-line setting through a new investigator-initiated trial to be conducted at the Oregon Health and Science University Knight Cancer Institute. This first-line design enables us to potentially have the greatest opportunity to impact these challenging diseases at an earliest possible stage, when the chances of patients responding to treatment are the highest. Finally, and important, this approach allows us to generate data in a capital-efficient manner. In September, we also presented the first look at data from an investigative-initiated trial in refractory extensive-stage small cell The trial treats patients with onvancitib monotherapy and is being conducted at the University of Pittsburgh Medical Center. Of the first seven patients that have been treated as of September 26, 2023, one had a confirmed partial response, three stable disease, and three progressive disease. Seeing a confirmed partial response, which the investigator assessed as a 50% shrinkage of the tumor from treatment with onvancitib monotherapy, provides a clear signal of Bonvancer-Tibb's efficacy in this challenging disease. Our current plans are to continue enrollment in this trial, but as we reported in September, our expectation is that a future clinical path forward in small cell lung cancer is most likely to include a combination regimen of Bonvancer-Tibb with second-line standard of care paclitaxel. Finally, the investigator initiated trial in triple negative breast cancer continues to enroll and we'll provide data from that trial when it becomes available. Okay, so, so far I've discussed our ongoing programs and plans. But our third objective to create value for our stakeholders is to investigate new therapeutic indications for advanced fertility. For example, The recent discovery of the power of the Onvancitib Bev combination indicates that we should aggressively explore through preclinical models indications where Bev is FDA approved. This includes RAS, wild-type colorectal cancer, lung, liver, kidney, cervical, and ovarian cancer. We also know that Onvancitib is anti-mitotic given that PLK1 plays a critical role in cellular mitosis, which is the process through which a cancer cell divides from one cell to two. There is extensive literature suggesting the combination of two antimitotic agents could be synergistic, and we have been exploring this combination in preclinical models with dramatic results. To give one example, I will share some new preclinical data for hormone receptor positive or HR positive breast cancer. These results are shown on slide eight. Breast cancer is the most common form of cancer diagnosed today in the United States, and hormone receptor or HR-positive breast cancer represents about 80 percent of breast cancer cases. In metastatic HR-positive breast cancer, tumor cells can develop resistance to first-line treatment, in part by overexpressing TLK1. Paclitaxel, an anti-metodic agent, is a common second-agent therapy, making it an ideal drug to explore in combination with onvansertib in this setting. The data on slide six shows how treatment with onvansertib, paclitaxel, and the two agents combined impact patient-derived xenograft models resistant to first-line treatment with pavloxacolib in HR-positive breast cancer. We observed highly significant tumor regression with the combination, with over 50% of the tumors within each model having a complete response to the combination treatment. As we look at this here at Cardiff Oncology, we believe this data supports our broader vision for Onvancer 2, and we remain committed to a cost-effective approach using preclinical models to validate additional indications and combinations. Now, I will turn it over to our CFO, Jamie Levine, to go over the financial results for the third quarter 2023. Jamie?